RU93056196A - N-CARBONYL SUBSTITUTED 5'-DESOXY-5-FLUORCITIDINE - Google Patents

N-CARBONYL SUBSTITUTED 5'-DESOXY-5-FLUORCITIDINE

Info

Publication number
RU93056196A
RU93056196A RU93056196/04A RU93056196A RU93056196A RU 93056196 A RU93056196 A RU 93056196A RU 93056196/04 A RU93056196/04 A RU 93056196/04A RU 93056196 A RU93056196 A RU 93056196A RU 93056196 A RU93056196 A RU 93056196A
Authority
RU
Russia
Prior art keywords
radical
formula
compounds
fluorcitidine
desoxy
Prior art date
Application number
RU93056196/04A
Other languages
Russian (ru)
Other versions
RU2135511C1 (en
RU2458932C2 (en
Inventor
Арасаки Мотохиро
Ишитсука Хидео
Курума Исами
Мива Масанори
Мурасаки Чикако
Шимма Нобуо
Умеда Исао
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU93056196A publication Critical patent/RU93056196A/en
Publication of RU2135511C1 publication Critical patent/RU2135511C1/en
Application granted granted Critical
Publication of RU2458932C2 publication Critical patent/RU2458932C2/en

Links

Claims (1)

Соединения общей формулы 1
Figure 00000001

в которой R1 представляет насыщенный или ненасыщенный, нормальный или разветвленный углеводородный радикал (в котором число атомов углерода в самой длинной прямой цепи составляет 3 - 7) или радикал формулы -(CH2)n-У, (где n = 0-4, если У представляет циклогексил, или n = 2 - 4, если У представляет низшую алкоксигруппу с 1 - 4 атомами углерода или фенил) и R2 представляет атом водорода или радикал, легко гидролизуемый в физиологических условиях, а также гидраты или сольваты соединений общей формулы 1 могут быть использованы для лечения опухолей. Соединения могут быть получены реакцией соединения формулы R1-OCOCl с N4-незамещенным 5'-дезокси-5-фторцитидином формулы 1, в которой R2 может представлять радикал для защиты гидроксигруппы, и, если необходимо, удалением защитных групп.Compounds of General Formula 1
Figure 00000001

in which R 1 represents a saturated or unsaturated, straight or branched hydrocarbon radical (in which the number of carbon atoms in the longest straight chain is 3 to 7) or a radical of the formula - (CH 2 ) n-Y , (where n = 0-4, if Y represents cyclohexyl, or n = 2-4, if Y represents a lower alkoxy group with 1 to 4 carbon atoms or phenyl) and R 2 represents a hydrogen atom or a radical easily hydrolyzable under physiological conditions, as well as hydrates or solvates of compounds of the general formula 1 can be used to treat tumors. Compounds can be prepared by reacting a compound of formula R 1 —OCOCl with an N 4 -substituted 5′-deoxy-5-fluorocytidine of formula 1, in which R 2 can be a radical to protect a hydroxy group, and, if necessary, by deprotection.
RU93056196/04A 1992-12-18 1993-12-16 N-oxycarbonyl-substituted 5-deoxy-5-fluorocytidines and pharmaceutical formulation RU2458932C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92121538.0 1992-12-18
EP92121538 1992-12-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012134029/04A Division RU2493162C1 (en) 1992-12-18 1993-12-16 N-oxycarbonyl-substituted 5'-deoxy-5-fluorocytidines and pharmaceutical preparation

Publications (3)

Publication Number Publication Date
RU93056196A true RU93056196A (en) 1997-03-27
RU2135511C1 RU2135511C1 (en) 1999-08-27
RU2458932C2 RU2458932C2 (en) 2012-08-20

Family

ID=8210304

Family Applications (2)

Application Number Title Priority Date Filing Date
RU93056196/04A RU2458932C2 (en) 1992-12-18 1993-12-16 N-oxycarbonyl-substituted 5-deoxy-5-fluorocytidines and pharmaceutical formulation
RU2012134029/04A RU2493162C1 (en) 1992-12-18 1993-12-16 N-oxycarbonyl-substituted 5'-deoxy-5-fluorocytidines and pharmaceutical preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012134029/04A RU2493162C1 (en) 1992-12-18 1993-12-16 N-oxycarbonyl-substituted 5'-deoxy-5-fluorocytidines and pharmaceutical preparation

Country Status (41)

Country Link
US (1) US5472949A (en)
EP (1) EP0602454B1 (en)
JP (1) JP2501297B2 (en)
KR (1) KR100347218B1 (en)
CN (1) CN1035617C (en)
AT (1) ATE137244T1 (en)
AU (1) AU671491B2 (en)
BG (1) BG61485B1 (en)
BR (1) BR9305089A (en)
CA (1) CA2103324C (en)
CZ (1) CZ284788B6 (en)
DE (1) DE69302360T2 (en)
DK (1) DK0602454T3 (en)
EE (1) EE03086B1 (en)
ES (1) ES2086856T3 (en)
FI (1) FI112365B (en)
GE (1) GEP20074251B (en)
GR (1) GR3020286T3 (en)
HK (1) HK1005875A1 (en)
HR (1) HRP931430B1 (en)
HU (2) HU218291B (en)
IL (1) IL108000A0 (en)
IS (1) IS4108A (en)
LT (1) LT3115B (en)
LV (1) LV10625B (en)
MY (1) MY109282A (en)
NO (1) NO300066B1 (en)
NZ (1) NZ250414A (en)
PH (1) PH30168A (en)
PL (1) PL174100B1 (en)
RO (1) RO112619B1 (en)
RU (2) RU2458932C2 (en)
SA (1) SA93140409B1 (en)
SI (1) SI9300648B (en)
SK (1) SK281403B6 (en)
SV (1) SV1993000080A (en)
TW (1) TW372239B (en)
UA (1) UA39158C2 (en)
UY (1) UY23697A1 (en)
YU (1) YU49411B (en)
ZA (1) ZA939293B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
GEP20043199B (en) * 1998-09-25 2004-03-25 Warner Lambert Co Use of Acetyldinaline in Combination with Gemcitabine, Capecitabine or Cisplatin for Chemotherapy of Cancer
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
CZ298259B6 (en) 2000-02-28 2007-08-08 Aventis Pharma S. A. Pharmaceutical combinations containing CPT-11 and capecitabine for treating cancer
AU2001246863A1 (en) * 2000-04-11 2001-10-23 Sayuri Yamada Curcumin compositions
KR100631754B1 (en) * 2000-08-09 2006-10-09 주식회사 코오롱 N-alkyloxycarbonyl-5-fluorocytosine derivatives and preparation method thereof
KR100730768B1 (en) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-deoxy-N-alkyloxycarbonyl-5-fluorocytosine-5'-carboxylic acid and its derivatives, and process for preparing thereof
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
PL369670A1 (en) 2002-01-14 2005-05-02 Novartis Ag Combinations comprising epothilones and anti-metabolites
JP4625637B2 (en) 2002-02-22 2011-02-02 シャイア エルエルシー Active substance delivery system and method for protecting and administering an active substance
CA2506085A1 (en) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
KR20080046752A (en) * 2003-12-22 2008-05-27 에프. 호프만-라 로슈 아게 Process for fluorocytidine derivatives
PL1848414T3 (en) 2005-02-03 2011-10-31 Wyeth Llc Method for treating gefitinib resistant cancer
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
RU2447889C2 (en) 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Method of treating cancer (versions)
EP1906977B1 (en) 2005-07-21 2012-02-22 Nuvo Research AG Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
PE20070763A1 (en) 2005-11-04 2007-08-08 Wyeth Corp ANTINEOPLASTIC COMBINATIONS OF AN INHIBITOR OF mTOR, TRASTUZUMAB AND / OR HKI-272
LT2474545T (en) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (en) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 Fluoropyrimidine compound carbalkoxylation method
ITMI20070435A1 (en) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2 ', 3'-DI-O-acyl-5-FLUORONUCLEOSIDI
US20100130734A1 (en) * 2007-04-20 2010-05-27 Dr. Reddy's Laboratories Ltd. Process for preparing capecitabine
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
LT3070090T (en) 2007-06-13 2019-06-25 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (en) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 Method for the preparation of capecitabine and method for the preparation of ?-anomer enriched trialkylcarbonate compound used therein
AR064165A1 (en) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie A PROCEDURE FOR THE PREPARATION OF CAPECITABIN AND INTERMEDIARIES USED IN THIS PROCEDURE
KR20090122955A (en) * 2008-01-03 2009-12-01 플러스 케미칼스, 에스.에이. Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102641270A (en) 2008-06-17 2012-08-22 惠氏有限责任公司 Antineoplastic combinations containing HKI-272 and vinorelbine
CN102202667A (en) 2008-08-04 2011-09-28 惠氏有限责任公司 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr Preparation of capecitabine
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
MX356593B (en) 2009-04-06 2018-06-05 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer.
FR2945211A1 (en) 2009-05-06 2010-11-12 Sanofi Aventis ANTITUMOR COMBINATION COMPRISING CABAZITAXEL AND CAPECITABINE
MY161416A (en) 2009-05-22 2017-04-14 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
CN102858791A (en) * 2009-07-23 2013-01-02 台湾神隆股份有限公司 Process for producing flurocytidine derivatives
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
AR081315A1 (en) 2010-03-10 2012-08-08 Incyte Corp HETEROCICLIC DERIVATIVES OF PIPERIDIN AND PIRIMIDIN -4-IL-AZETIDINA, A CRYSTALLINE FORM OF THE SALT OF ACETONITRILADIPICO ACID OF A PYRIMIDINIC DERIVATIVE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME THINGS WITH THE TREATMENT OF INJECTION , T
LT3117709T (en) 2010-03-12 2018-11-26 Genzyme Corporation Combination therapy for treating breast cancer
ME02445B (en) 2010-05-21 2016-09-20 Incyte Holdings Corp Topical formulation for a jak inhibitor
CN102260309B (en) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 Method for preparing high-purity capecitabine
AR083933A1 (en) 2010-11-19 2013-04-10 Incyte Corp PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS
CN102558262A (en) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 Preparation method of high-purity capecitabine
PE20140832A1 (en) 2011-06-20 2014-07-14 Incyte Corp DERIVATIVES OF AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE AS JAK INHIBITORS
CN102266303A (en) * 2011-07-07 2011-12-07 程雪翔 Capecitabine medicinal composition and preparation method thereof
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
CN102516338B (en) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 Capecitabine compound, pharmaceutical composition and preparation method thereof
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
CA3178452A1 (en) 2012-11-15 2014-05-22 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
LT3489239T (en) 2013-03-06 2022-03-10 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
WO2015026818A1 (en) * 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (en) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 Preparation method of capecitabine isomer
US9937261B2 (en) 2014-06-09 2018-04-10 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
CN104530164A (en) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 Synthesis technology for capecitabine
KR20160117060A (en) 2015-03-31 2016-10-10 이승주 Baby table
CN105646625B (en) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 A kind of preparation method of capecitabine
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (en) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi THE USE OF SERANIB-2 IN THE TREATMENT OF LUNG CANCER AND BREAST CANCER
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CA3087565A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2020010322A (en) 2018-03-30 2022-11-30 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors.
US20220087975A1 (en) 2019-01-11 2022-03-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
DE3587500T2 (en) * 1984-12-04 1993-12-16 Lilly Co Eli Tumor treatment in mammals.
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Similar Documents

Publication Publication Date Title
RU93056196A (en) N-CARBONYL SUBSTITUTED 5'-DESOXY-5-FLUORCITIDINE
TW372239B (en) N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
ES470159A1 (en) Components of catalysts for polymerizing alpha-olefins and the catalysts formed from the components
KR950002755A (en) Inhibition of phosphatidylinositol 3-kinase by wortmannin and its analogs
KR840005445A (en) Method for preparing xanthine derivative
FI830397A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV IMIDAZOLIDINDERIVAT
FR2450805A1 (en) SUBSTITUTED STABILIZING ALKYL HYDROQUINONE CARBONATES FOR OLEFIN POLYMERS
EP0338937A3 (en) 1-û3-(4-hydroxy-phenyl)-1-hydoxy-1-propyl¨-2-(amino-alkyleneoxy)-benzene derivatives, process for their preparation and their therapeutical use
CA2018149A1 (en) Aminoketone compounds
KR950703524A (en) Non-Metabolizable Clomiphene Analogs for Treatment of Tamoxifen-Resistant Tumors
KR910009720A (en) Alkoxymethylidene Epipodophyllotoxin Glycosides
JPH022875B2 (en)
RU94005002A (en) COMPOUNDS, METHOD OF OBTAINING, PHARMACEUTICAL COMPOSITION, METHOD OF TREATING OSTEOPOROSIS